- Kinetics and mechanism for reduction of oral anticancer platinum(iv) dicarboxylate compounds by L-ascorbate ions
-
Ascorbate(Asc) reductions of the oral anticancer platinum(iv) prodrugs m,trans,cu-[PtCl2(OAc)2(cha)(NH 3)](JM216) and cis, trans;,cis-[PtCl2(OCOC3H7) 2(cha)(NH3)](JM221) and of the isomers of JM216, viz.trans,cis,cis-[PtCl2(OAc)2(cha)(NH3)](JM394) and trans,trans,trans-[PtCI2(OAc)2(cha)(NH 3)](JM576)(OAc = acetate, cha = cyclohexylamine) have been investigated in a 1.0 M aqueous perchlorate medium using stopped-flow and conventional UV/VIS spectrophotometry as a function of temperature and pH. JM216 and 221 are reduced to ra-[PtCl2(cha)(NH3)](JM118) and JM394 and 576 to CM- and trans-[Pt(OAc)2(cha)(NH3)], respectively. The redox reactions follow the second-order rate law: -d[Pt(iv)]/dt = k [Pt(iv)] [Asc]tot where k is a pH dependent second-order overall rate constant and [Asc]tot = [Asc2-] + [H2Asc] + [H2Asc]. Reduction of JM216 and JM221 is slow(overall rate constants k298 = 5.08 ±10-2 and 3.25 × 1(T2 mol-1 dm3 s-1 at pH 7.12, respectively) and is suggested to take place via an outer-sphere mechanism. Reductions of JM394 and JM576 are more than three orders of magnitude faster(k298 = 230 ±6 mol-1 dm3 s-1 at pH 7.0 for JM394). They are suggested to take place by a mechanism involving a reductive attack on one of the mutually trans chloride ligands by Asc2 and less efficiently by H Asc- leading to the formation of a chloride-bridged activated complex. The second-order rate constants for reduction of JM394 by HAsc- and Asc2- at 25 °C are 0.548 ±0.004 and(4.46 ±0.01) × 106 mol-1 dm3 s-1, respectively. The rate constants for reduction of JM216 and JM221 by Asc2- at 25 °C are calculated to be 672 ±15 and 428 ±10 mol1 dm3 s-1, respectively and reduction by HAsc- was not observed under these conditions. Thus, Asc2- is up to 7 orders of magnitude more efficient as a reductant than HAsc-. H2Asc is virtually inactive. The activation parameters Asc2- and AS+ for reduction of JM216, JM221, JM394, and JM576 by Asc2- are 52 ±1,46 ±1, 56.2 ±0.5, and 63 ±2 kJ mol-1 and -97 ±4, -120 ±4, -24 ±2, and -8 ±5 J K-1 mol-1, respectively. An isokinetic relationship gives further support to the mechanistic assignments. The Royal Society of Chemistry 2000.
- Lemma, Kelemu,Sargeson, Alan M.,Elding, Lars I.
-
-
Read Online
- Platinum(IV) cisplatin derivative trans, cis, cis-bis(heptanoato)amine(cyclohexylamine)dichloridoplatinum(IV) has an enhanced therapeutic index compared to cisplatin for the treatment of non-small cell lung cancer
-
Lung cancer is the leading cause of cancer-related death in the United States, and non-small cell lung cancer (NSCLC) the most common type. Platinum (Pt) anticancer agents, such as cisplatin, remain a mainstay in the clinic; however, these agents are not tumor-specific and, thus, the patient experiences negative side-effects. We here prepare trans, cis, cis-bis(heptanoato)amine(cyclohexylamine)dichloridoplatinum(IV) and demonstrate that it is greater than 50-fold more toxic toward NSCLC cells than is cisplatin. Furthermore, it has a much improved therapeutic index. This Pt(IV) complex binds to DNA in a manner similar to that of cisplatin, and can be incorporated into mesoporous silica nanoparticles for fine-controlled release and the targeting of tumors.
- Shi, Yi,Koneru, Bhuvaneswari,Redfearn, Warren,Miller, Michael L.,Myers, Lara,Di Pasqua, Anthony J.
-
-
Read Online
- Dependence of the reduction products of platinum(IV) prodrugs upon the configuration of the substrate, bulk of the carrier ligands, and nature of the reducing agent
-
Most evidence indicates that platinum(IV) prodrugs are rapidly reduced under physiological conditions by biologically relevant reducing agents, such as ascorbic acid and glutathione; however, the precise mechanisms of reduction are not fully understood, thus preventing rational design of compounds with better pharmacological properties. In the present study, reduction of three all-trans platinum(IV) compounds of formula [PtCl2(CH3COO) 2LL′] (LL′ = {E-HN = C(CH3)OCH 3}2, 1c, (H3N)(cyclohexylamine), 2c, and (H3N)(1-adamantylamine), 3c) by two biologically relevant reductants (ascorbic acid and glutathione) and by a classical coordination chemistry reductant (triphenylphosphine) has been investigated. Reduction by triphenylphosphine and glutathione leads, in all cases examined, to loss of the two chlorides and formation of the diacetato species trans-[Pt(CH 3COO)2LL′]. This is in accord with an inner-sphere redox process in which a chlorido ligand bridges the reductant with the platinum(IV) center. In contrast, reduction by ascorbic acid/sodium ascorbate 1:1 leads, in addition to the diacetato complex, also to formation of a significant amount of dichlorido species, particularly in the case of 1c (31%) and to a lesser extent of 3c (16%). The latter results indicate that ascorbic acid is less efficient to promote an inner-sphere redox process (attack on a chlorido ligand), therefore allowing participation of an outer-sphere mechanism, ultimately leading to formation of the more stable dichlorido species. The dependence of the yield of diacetato species upon the steric hindrance of the carrier ligand (69%, 84%, and 95% for 1c, 3c, and 2c, respectively) points to the possible participation of a second type of inner-sphere mechanism in which the interaction between the ascorbate and a chlorido ligand of the platinum(IV) substrate is mediated by a platinum(II) catalyst, the transition state resembling that of a platinum(II)-catalyzed ligand substitution at a platinum(IV) center. This investigation demonstrates that different species can be obtained by reduction of a platinum(IV) prodrug (depending upon the configuration of the substrate and the nature of the intervening reducing agent) and can explain some lack of correlation between prodrug and putative active species as well as contrasting literature results.
- Sinisi, Marilù,Intini, Francesco P.,Natile, Giovanni
-
p. 9694 - 9704
(2012/10/29)
-
- pKa values of aqua ligands of platinum(II) anticancer complexes: [1H, 15N] and 195Pt NMR studies of cis- and trans-[PtCl2 (NH3)(cyclohexylamine)]
-
Syntheses and NMR studies are reported of two 15N-labelled Pt(II) complexes of anticancer interest: cis-[PtCl2(15NH3)(c-C6H 1115NH2)], a metabolite of the orally-active Pt(IV) complex cis,trans,cis-[PtCl2(acetate)2(c-C6H 11NH2)(NH3)], and trans-[PtCl2(15NH3)(c-C6H 1115NH2)], a reduction product of the active Pt(IV) complex trans,trans,trans-[PtCl2(OH)2(c-C6H 11NH2)]. For cis-[PtCl2(15NH3)(c-C6H 1115NH2)], hydrolysis was faster for the chloride ligand trans to cyclohexylamine, and the pKa values determined by [1H, 15N] NMR spectroscopy for the two cis monoaqua isomers were the same (6.73). The trans monoaqua complex was a stronger acid with pKa of 5.4 (determined by 195Pt NMR). For the cis diaqua complex, pKa values of 5.68 and 7.68 were determined.
- Barton, Sarah J.,Barnham, Kevin J.,Habtemariam, Abraha,Sue, Rodney E.,Sadler, Peter J.
-
-
- Crystal and Molecular Structures of Asymmetric cis- and trans-Platinum(II/IV) Compounds and Their Reactions with DNA Fragments
-
The asymmetrically substituted platinum(II) complexes cis-Pt(NH3)(c-C5H11NH2)Cl 2 and trans-Pt(NH3)(c-C6H11-NH2)Cl 2 have been synthesized and their crystal structures have been determined. Crystals of cis-Pt(NH3)(c-C6H11NH2)Cl 2 (1) are orthorhombic, space group Pbca (no. 61) with a = 10.1994(12), b = 10.494(2), c = 18.826(2) ?, Z = 8. The structure refinement converged to R1 = 0.0518 and wR2 = 0.1143. Crystals of trans-Pt(NH3)(c-C6H11NH2)Cl 2 (2) are monoclinic, space group P21/c (no. 14) with a = 12.141(3), b = 6.0965(9), c = 19.864(3) ?, β= 118.71(2)°, Z = 4. The structure refinement converged to R1 = 0.0711 and wR2 = 0.1846. In addition, the Pt(IV) analogues with axial hydroxide ligands have been synthesized. Also the corresponding bis(carboxylato)-platinum(IV) compound of formula trans,cis,cis-Pt(NH3)(c-C6H11NH 2)Cl2(OOCCH3)2 has been obtained by conversion of the hydroxide with acetic anhydride. Reactions of these platinum complexes with 9-methylhy-poxanthine and guanosine-5′-monophosphate (5′-GMP) have been studied in significant detail. The course of the reactions was followed by NMR spectroscopy, and 1H and 195Pt techniques were used to identify the formation of the products. It was found that the Pt(II) compounds easily react with the bases at the N7 position, whereas the Pt(IV) compounds react very slowly (for trans,cis,cis-Pt(NH3)(c-C6H11NH 2)Cl2(OOCCH3)2) or not at all (for trans,trans,trans-Pt(NH3)(c-C6H11NH 2)Cl2(OH)2). Only in the presence of glutathione does a reaction of the latter with 5′-GMP takes place. In this case a major product was found to be the reduced trans-Pt(II) complex with one molecule of 5′-GMP and one molecule of S-bonded glutathione.
- Talman, Eduard G.,Brüning, Wolfgang,Reedijk, Jan,Spek, Anthony L.,Veldman, Nora
-
p. 854 - 861
(2008/10/09)
-
- Carboxylation of kinetically inert platinum(IV) hydroxy complexes. An entrée into orally active platinum(IV) antitumor agents
-
Carboxylation of hydroxide coordinated to Pt(IV) by anhydrides, pyrocarbonates, and isocyanates to form the corresponding Pt(IV) carboxylates, carbonates, and carbamates is described. For example, the acylation with acetic anhydride of (OC-6-33)-amminedichloro(cyclohexanamine)dihydroxyplatinum(IV) leads to formation of (OC-6-43)-bis(acetato-O)amminedichloro(cyclohexanamine)platinum(IV) (JM-216) in 60% yield. This compound is currently in worldwide clinical trials as an orally active antitumor agent. Pt(IV) dicarbonates and dicarbamates are prepared similarly by reaction of a Pt(IV) hydroxide with a pyrocarbonate or isocyanate. The carboxylation reaction can be used to prepare molecules containing ligands with pendant functional groups that would be difficult to introduce by substitution reactions. Thus (OC-6-43)-amminedichloro(cyclohexanamine)bis((methylthio)acetato-O)platinum(IV) was prepared, which was oxidized to the corresponding sulfoxide (OC-6-43)-amminedichloro-(cyclohexanamine)bis((methylsulfinyl)acetato-O) platinum(IV). Finally, unsymmetrical carboxylate complexes may be obtained by reaction of a binary mixture of two electrophiles with a Pt(IV) hydroxide followed by chromatographic separation of the carboxylation products. A simplified synthesis of the K[PtIICl3NH3] in 55% yield from cisplatin is also reported. This improves the availability of molecules of the general formula cis-PtII-Cl2AA′ (A, A′ = ammine, amine) which are critical intermediates in the multistep synthesis of the Pt(IV) carboxylates having antitumor activity.
- Giandomenico, Christen M.,Abrams, Michael J.,Murrer, Barry A.,Vollano, Jean F.,Rheinheimer, Melanie I.,Wyer, Sandra B.,Bossard, Gerald E.,Higgins III, John D.
-
p. 1015 - 1021
(2008/10/08)
-